Medivation, Inc. is a biopharmaceutical company focused on the rapid development of novel small molecule drugs to treat critically ill patients with serious diseases for which there are limited treatment options. Medivation aims to transform the treatment of these diseases and offer hope to critically ill patients and their caregivers.
MDV3100We have completed patient enrollment in a Phase 1-2 clinical trial of our novel, triple-acting oral androgen receptor antagonist MDV3100 in patients with metastatic castration-resistant (also known as hormone refractory) prostate cancer (CRPC), an advanced stage of the disease. To read about MDV3100's mechanism of action and the efficacy and safety results from this trial published in The Lancet, please click here. Click here for Science article. Medivation, in collaboration with Astellas, is currently evaluating MDV3100 in a comprehensive development program for both early- and late-stage prostate cancer. The Phase 3 AFFIRM trial is currently enrolling men with castration-resistant prostate cancer who were previously treated with docetaxel-based chemotherapy. In addition, the companies are on track to initiate three new MDV3100 trials in earlier-stage prostate cancer in 2010 including: a Phase 3 trial in men with chemotherapy-naïve castration-resistant prostate cancer; a Phase 2 head-to-head trial comparing MDV3100 with bicalutamide; and a Phase 1 trial in hormone-naive patients. For more information about our clinical studies, please contact Medivation at This e-mail address is being protected from spambots. You need JavaScript enabled to view it . To learn more about clinical trials, please visit www.clinicaltrials.gov, a service of the U.S. National Institutes of Health.
|
 |
 |
| Medivation © 2010 |